Summit Wealth Group LLC Co. Has $832,000 Stake in Johnson & Johnson $JNJ

Summit Wealth Group LLC Co. decreased its stake in Johnson & Johnson (NYSE:JNJ) by 56.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,021 shares of the company’s stock after selling 5,308 shares during the quarter. Summit Wealth Group LLC Co.’s holdings in Johnson & Johnson were worth $832,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. WealthCollab LLC lifted its stake in Johnson & Johnson by 4.7% in the fourth quarter. WealthCollab LLC now owns 1,015 shares of the company’s stock valued at $210,000 after buying an additional 46 shares during the period. MMA Asset Management LLC increased its holdings in shares of Johnson & Johnson by 1.3% in the fourth quarter. MMA Asset Management LLC now owns 3,600 shares of the company’s stock worth $745,000 after acquiring an additional 46 shares in the last quarter. Vista Investment Partners II LLC increased its holdings in shares of Johnson & Johnson by 1.2% in the fourth quarter. Vista Investment Partners II LLC now owns 3,811 shares of the company’s stock worth $789,000 after acquiring an additional 47 shares in the last quarter. Campbell Deegan Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 1.6% in the fourth quarter. Campbell Deegan Wealth Management LLC now owns 2,990 shares of the company’s stock worth $619,000 after acquiring an additional 48 shares in the last quarter. Finally, Finivi Inc. increased its holdings in shares of Johnson & Johnson by 2.0% in the fourth quarter. Finivi Inc. now owns 2,458 shares of the company’s stock worth $509,000 after acquiring an additional 48 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 2.8%

NYSE:JNJ opened at $230.43 on Thursday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market cap of $554.69 billion, a PE ratio of 26.64, a PEG ratio of 2.20 and a beta of 0.27. Johnson & Johnson has a 52-week low of $146.12 and a 52-week high of $251.71. The stock has a 50-day simple moving average of $235.82 and a 200 day simple moving average of $221.47.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period last year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a $1.34 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is 60.12%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Leerink Partners upgraded Johnson & Johnson from “Market Perform” to “Outperform” and lifted its price target to $265 from $252, citing accelerating growth prospects from new drug launches and stronger oncology and immunology franchises. Johnson & Johnson upgraded at Leerink on growth prospects
• Positive Sentiment: Analysts highlighted J&J’s pipeline momentum, including Tremfya and newly approved Icotyde as key drivers for immunology growth as Stelara faces biosimilar pressure, reinforcing the company’s post-Stelara strategy. Tremfya, Icotyde Lead J&J’s Post-Stelara Immunology Strategy
• Positive Sentiment: J&J also announced the global launch of the Shockwave C2 Aero Coronary IVL Catheter, adding another product launch that supports its cardiovascular growth story. Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
• Neutral Sentiment: J&J remains in focus as a defensive, high-quality name with one of the market’s strongest credit ratings, which may keep income-focused investors interested but is less likely to be a near-term catalyst. The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio
• Neutral Sentiment: The company also got attention in articles emphasizing its safety, dividend appeal, and retirement-portfolio status, which supports the stock’s defensive reputation rather than signaling a major fundamental change. Russell 1000 Dividend ETF Hits 125 as Johnson & Johnson Leads The Safety Test

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on JNJ shares. Weiss Ratings downgraded Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a report on Friday, April 24th. The Goldman Sachs Group increased their price target on Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Wells Fargo & Company increased their price target on Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a report on Wednesday, April 15th. Citigroup increased their price target on Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Finally, Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target for the company in a report on Wednesday. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $253.04.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares in the company, valued at $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 30,142 shares of company stock valued at $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.